Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|December 17, 2017
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A Jones, Anthony R Mato, William G Wierda, et al.
American Journal of Hematology|February 19, 2015
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemiaAnthony R Mato, Kenneth A Foon, Tatyana Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Blood|June 22, 2018
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphomaJakub Svoboda, Susan R Rheingold, Saar I Gill, et al.
British Journal of Haematology|March 26, 2014
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphomaTatyana Feldman, Anthony R Mato, Kar F Chow, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.
Blood Advances|July 23, 2021
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformationOscar B Lahoud, Sean M Devlin, Molly A Maloy, et al.
The New England Journal of Medicine|August 1, 2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D Shanafelt, Xin V Wang, Neil E Kay, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 6, 2001
Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis: comparison of results obtained in a multilaboratory effort using identical protocols and MRSA strainsM Chung, H de Lencastre, P Matthews, et al.
Pageof 12